Alchemab

Alchemab builds a platform that identifies novel drug targets and therapeutics by analyzing patient antibody repertoires using deep B cell sequencing and computational analysis. Targeting neurodegenerative diseases and oncology, the company collaborates with various stakeholders, including patient groups and academic institutions, leveraging a vast antibody dataset and advanced models like AntiBERTa and FAbCon.